Valerio Therapeutics completes acquisition of Etherna Immunotherapies
Bitget2026/10/12 06:19- Valerio Therapeutics completed the acquisition of Etherna Immunotherapies, taking 100% of its share capital and voting rights.
- Deal valued Etherna at an enterprise value of EUR 30 million, funded through cash consideration and share consideration.
- Cash portion was funded via issuance of 68,220,333 new ordinary shares at EUR 0.59 each, raising about EUR 40.25 million.
- Transaction expands an integrated RNA platform spanning nucleic acid chemistry, lipid nanoparticle delivery, targeted moiety engineering, manufacturing.
- Post-transaction share capital totals 587,615,993 shares, with Artal International holding 42.6%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"The Big Short" Burry shifts to Nasdaq and semiconductor ETF put options, warning of a market peak within 9 months
Investor Michael Burry, known for accurately identifying major flaws in the U.S. subprime mortgage market and predicting the 2008 financial crisis, has concentrated most of his bearish bets on put options for the Nasdaq 100 Index (NDX) and the VanEck Semiconductor ETF (SMH).
Morgan Stanley's Wilson: The bond market is already “raising rates” for the Fed, two major signals needed for a US stock rebound
Morgan Stanley believes that since February, U.S. Treasury yields have risen by 120 basis points in total, with a stronger dollar and high oil prices further tightening financial conditions. The bond market is currently replacing the Federal Reserve in exerting tightening pressure. Whether U.S. stocks can rebound depends on two key signals: whether the MOVE index falls back and whether JPMorgan, Goldman Sachs, Citigroup, and Wells Fargo can deliver positive earnings reports. Wilson believes that market concerns over recession risks may be excessive and that there is still room for improvement in U.S. equities.
Crypto prices
More
